Requests · San Jacinto College

Scaling the Pharmaceutical Manufacturing Workforce (Joint with Alvin College)

Priority 1 · one of 2 items in the San Jacinto College's request for 2028-29 · The item begins on page 22 of the request

This is a request, not an appropriation.

Figures under review. The request states this item's figures in more than one place and they do not agree, or they have not been checked, so none is shown here. See the request itself.

The agency's justification

San Jacinto College requests $30 million as its share of a $42 million joint exceptional item with Alvin College to strengthen and expand advanced (bio)manufacturing workforce training capacity serving the Generation Park area, the Texas Medical Center, and the 288 Life Sciences Corridor. Alvin College is submitting a companion request for its $12 million share of the joint item, supporting its development and launch of a new advanced manufacturing training center, inclusive of a purpose-built biomanufacturing workforce training program, to be located in Pearland, Texas. This investment builds on documented industry commitment already on the ground, including Eli Lilly's $6.5 billion investment in the Houston life sciences region, Bristol Myers Squibb's $2.3 billion investment in the same Generation Park footprint, and a Memorandum of Understanding with the Texas Medical Center. San Jacinto College's existing partnership with the National Institute for Bioprocessing, Research, and Training (NIBRT) and its operational biomanufacturing program position San Jac to scale training capacity quickly against the current demand and expected growth. Funding will expand laboratory space, acquire advanced equipment, and build shared training infrastructure at Generation Park to serve both San Jacinto College and Alvin College students as well as employers’ upskilling request to meet the regional workforce needs of employers . Structuring the request jointly reflects a coordinated regional approach over duplicative single institution requests.

External and internal factors

The industrial biomanufacturing and biopharmaceutical sectors are growing rapidly in Texas and carry national security and strategic economic importance for the United States. Current estimates put the biomanufacturing industry's growth trajectory between four and thirty trillion dollars ($4-30 T USD). History shows that a single large capital biopharmaceutical project in a new region draws additional companies and forms an industry hub, and Generation Park is positioned to become that hub given Eli Lilly's commitment and continued interest from the Texas Medical Center. Texas competes directly with North Carolina and other East Coast biopharmaceutical hubs, as well as emerging Midwest hubs, for site selection. Those regions currently field more aggressively funded workforce programs that can deliver trained manufacturing technicians faster. The Greater Houston region holds an advantage given its existing chemical manufacturing infrastructure and the opportunity of transitioning that workforce into biomanufacturing roles, many of which will be in an advanced manufacturing setting. The state needs to invest now to secure that advantage before it goes to a competing region.

As marked in the request